An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Official Title

A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

Summary:

The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer

Trial Description

Primary Outcome:

  • Objective Response Rate (ORR)
  • Duration of Response (DOR)
  • Progression-free Survival Rate (PFSR)
Secondary Outcome:
  • Safety and tolerability of Nivolumab based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths
  • Safety and tolerability of Nivolumab & Dasatinib combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths
  • Safety and tolerability of Nivolumab & BMS-986016 combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths
  • Safety and tolerability of Nivolumab & Ipilimumab combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths
  • Safety and tolerability of Nivolumab & BMS-966205 combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society